Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Pyxis Oncology (PYXS) over the last 2 years, with Q2 2025 value amounting to 652.77%.

  • Pyxis Oncology's EBITDA Margin changed N/A to 652.77% in Q2 2025 from the same period last year, while for Sep 2025 it was 3452.77%, marking a year-over-year change of. This contributed to the annual value of 478.29% for FY2024, which is N/A changed from last year.
  • Per Pyxis Oncology's latest filing, its EBITDA Margin stood at 652.77% for Q2 2025.
  • Pyxis Oncology's EBITDA Margin's 5-year high stood at 20.93% during Q1 2024, with a 5-year trough of 652.77% in Q2 2025.